Lannett Company security is likleyly to rally in the upcoming sessions.

The pharmaceutical company displays high-quality fundamentals with attractive valuation levels and a strong profitability. Analysts estimartes shows the great growth potential of the business, regularly revising upward earnings estimates. Indeed they are keeping a buyer bias with a target price of USD 63.3 on average, which represents a huge gain potential of 44%.

Technically, shares are trading on a negative configuration in the short term but still in a bullish trend on the long term. Prices consolidated on contact with the upward trendline and they seems to rebound now after hitting the 42.28 mid term support on weekly data. This movement is likely to continue in order to reach the USD 49.5 short term resistance then the USD 57.50 level.

It is advisable to take a long position on the stock to benefit from the potential technical rebound. The target price will be set at USD 49.51. A stop loss should be placed under the current support.